A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells

Published:2013-08 Issue:2 Volume:24 Page:182-196
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Petrocca Fabio,Altschuler Gabriel,Tan Shen Mynn,Mendillo Marc L.,Yan Haoheng,Jerry D. Joseph,Kung Andrew L.,Hide Winston,Ince Tan A.,Lieberman Judy

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference44 articles.

1. Prospective identification of tumorigenic breast cancer cells;Al-Hajj;Proc. Natl. Acad. Sci. USA,2003

2. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study;Awada;Br. J. Cancer,2008

3. Sequence analysis of mutations and translocations across breast cancer subtypes;Banerji;Nature,2012

4. Will the ubiquitin system furnish as many drug targets as protein kinases?;Cohen;Cell,2010

5. Reactome: a database of reactions, pathways and biological processes;Croft;Nucleic Acids Res.,2011

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer;Breast Cancer Research and Treatment;2024-08-23

2. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer;British Journal of Cancer;2024-07-05

3. Understanding the Transcription Factor NFE2L1/NRF1 from the Perspective of Hallmarks of Cancer;Antioxidants;2024-06-22

4. Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts;Scientific Reports;2024-06-19

5. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer;Journal of Medicinal Chemistry;2024-06-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3